* β-arrestins are critical regulator and transducer proteins for G-protein-coupled receptors (GPCRs). β-arrestin is widely believed to be activated by forming a stable and stoichiometric GPCR-β-arrestin scaffold complex, which requires and is driven by the phosphorylated tail of the GPCR. Here we demonstrate a distinct and additional mechanism of β-arrestin activation that does not require stable GPCR-β-arrestin scaffolding or the GPCR tail. Instead, it occurs through transient engagement of the GPCR core, which destabilizes a conserved inter-domain charge network in β-arrestin. This promotes capture of β-arrestin at the plasma membrane and its accumulation in clathrin-coated endocytic structures (CCSs) after dissociation from the GPCR, requiring a series of interactions with membrane phosphoinositides and CCS-lattice proteins. β-arrestin clustering in CCSs in the absence of the upstream activating GPCR is associated with a β-arrestindependent component of the cellular ERK (extracellular signal-regulated kinase) response. These results delineate a discrete mechanism of cellular β-arrestin function that is activated catalytically by GPCRs.
Flag-β1AR (blue) (a) or Flag-β2AR (blue) (c), β-arrestin-2-GFP (green) and clathrin-light-chain-DsRed (red) before and after treatment with 10 µM isoproterenol (Iso). b, d, Mean enrichment of Flag-β1AR (b) and Flag-β2AR (d) at CCSs after treatment with 10 µM isoproterenol. n = 14 and 15 cells, respectively, from three independent experiments; data shown as mean ± s.e.m. e, Live-cell TIRF microscopy images of HEK 293 cells co-expressing immobilized super-ecliptic pHluorin-β2AR (blue), β-arrestin-2-mApple (green) and clathrin light chain-TagBFP (red) before and after treatment with 10 µM isoproterenol. f, Time-lapse images of individual pre-existing CCSs from e. Scale bars, 5 µm. a, c, e and f show representative images from three independent experiments.
Article reSeArcH β1AR activation, as it was greatly reduced by the β1-selective antagonist CGP 20712A (Extended Data Fig. 1a ) or in HEK 293 cells that did not express recombinant β1ARs (Extended Data Fig. 1b) . In H9c2 cells, which natively express β1ARs at higher levels 14 , either isoproterenol or the β1-selective agonist dobutamine activated β-arrestin trafficking through endogenous receptors (Extended Data Fig. 1c ) and the β1-selective antagonist CGP 20712A inhibited this (Extended Data  Fig. 1d ). We also found that β-arrestin-1 (also known as arrestin-2) is capable of separate accumulation in CCSs (Extended Data Fig. 1e-g ), establishing generality across β-arrestin isoforms.
The β2-adrenergic receptor (β2AR) is a homologous GPCR that co-accumulates with β-arrestin in CCSs [15] [16] [17] . We verified this by TIRF microscopy in HEK 293 cells expressing Flag-tagged β2ARs at levels around tenfold higher than endogenous levels (Fig. 1c, d , Extended Data Fig. 1h ). We considered the possibility that β2ARs can also activate β-arrestin trafficking separately from the receptor, but that this capacity is obscured by the natural tendency of β2ARs to co-traffic. Indeed, when laterally immobilized to prevent receptor accumulation in CCSs 18, 19 , Flag-β2AR still promoted rapid accumulation of β-arrestin-2 in CCSs (Fig. 1e , f, Extended Data Fig. 1i, j) . Furthermore, when not immobilized, both β1AR and β2AR produced super-stoichiometric accumulation of β-arrestin-2 in CCSs relative to receptor (around 28-and 4-fold, respectively; Extended Data Fig. 1k-m) . Moreover, a limited survey of family A GPCRs suggested that such differential activation of β-arrestin trafficking is broadly conserved across GPCRs as well as across β-arrestin isoforms (Extended Data Fig. 2 ).
Activation by GPCR core interaction
Canonical GPCR-β-arrestin scaffolding requires the receptor cytoplasmic tail and is driven by phosphorylation of the tail [20] [21] [22] [23] . By contrast, the β1AR cytoplasmic tail was not required to activate β-arrestin trafficking. β-arrestin accumulation in CCSs was unaffected by nearly complete removal of the GPCR cytoplasmic tail (415T, Extended Data Fig. 3a, b ). This was also true for β2ARs after a similarly extensive tail truncation (341T, Fig. 2a, b) , as well as after a less extensive truncation (365T) that was previously shown to abrogate β2AR-β-arrestin scaffold complex formation 9 (Extended Data Fig. 3c -e). In principle, GPCRs could promote tail-independent trafficking of β-arrestin through activation of a downstream G-protein-linked signalling pathway. We found that this was not the case, as GPCR-activated β-arrestin-2 accumulation in CCSs did not depend on selectivity for G protein coupling, and trafficking activated by the G i -coupled D2 dopamine receptor (DRD2) was unaffected by pertussis toxin (Extended Data Fig. 3f-h ), consistent with a recent report 24 . Further, receptorindependent activation of adenylyl cyclase using forskolin did not promote (or block) β-arrestin-2 trafficking (Extended Data Fig. 3i-k) . Rather, the discrete β-arrestin trafficking behaviour required direct binding of the ligand-activated GPCR, because a mutant β-arrestin-2 that is unable to bind GPCRs 25 did not accumulate in CCSs (Extended Data Table 1 ; Extended Data Fig. 3l-n) . β-arrestin has been shown to engage GPCRs weakly through a ligand-dependent interaction that does not require the phosphorylated receptor tail 26 . We hypothesized that transient binding is sufficient to activate β-arrestin trafficking and is mediated by the GPCR core. To test this, we focused on DRD2 because it has a short cytoplasmic tail and yet robustly activates β-arrestin trafficking to CCSs (Extended Data Fig. 2g-i) . A mutation in the core of DRD2 that specifically disrupts coupling of the receptor to β-arrestin (DRD2(G prot) 27 ) prevented ligand-dependent stimulation of β-arrestin trafficking to CCSs (Fig. 2c-e) , establishing a critical role for the interaction with the receptor core.
We next investigated how engagement with the receptor core affects the activation of β-arrestin trafficking by focusing on a polar region in β-arrestin that is located proximal to the conserved finger loop and is thought to directly contact the ligand-activated GPCR core 10, 21 . We identified three charged residues in this 'finger-loop-proximal' region that produce constitutive β-arrestin-2 accumulation in CCSs when mutated to alanine (R77A, K78A, D79A; Fig. 3a, b) . When analysed using a statistical metric of β-arrestin clustering validated against a previously described constitutively active β-arrestin construct (polar core mutant 28 ; Extended Data Table 1 , Extended Data Fig. 4a, b) , these finger-loop-proximal alanine substitutions produced a comparably strong constitutive activation phenotype (Extended Data Fig. 4b ). The finger-loop-proximal charge mutations also increased ligandindependent interaction of β-arrestin with the clathrin-associated adaptor protein-2 (AP-2; Extended Data Fig. 4c-e) , providing biochemical evidence for constitutive activation of β-arrestin. Individual substitution of finger-loop-proximal charged residues was sufficient to produce ligand-independent accumulation of β-arrestin-2 in CCSs, with the K78A mutation having the largest effect (Extended Data Fig. 4b , f-h). Further, mutating K78 to arginine (K78R) rather than alanine did not produce constitutive activation (Extended Data Fig. 4b, i) . Together, these results suggest that K78 stabilizes β-arrestin in its inactive (cytoplasmic) state through a charge interaction positioned at the GPCR core-binding interface.
To investigate how these residues may affect β-arrestin function, we focused on β-arrestin-1, because more structural data are available for this isoform than for β-arrestin-2 and mutating the corresponding residues in β-arrestin-1 produced constitutive accumulation in CCSs (Fig. 3c) . Crystal structures of putative inactive (Extended Data Fig. 5a left, middle) and active (Extended Data Fig. 5a right) forms of β-arrestin-1 reveal that the finger-loop-proximal charged residues are located within an extensive network of polar residues spanning the N and C domains of β-arrestin. In both inactive and active structures, R76 may interact with D78 (corresponding to R77 and D79 in Fig. 2 | Activation of β-arrestin trafficking requires the GPCR core but not the GPCR cytoplasmic tail. a, Live-cell TIRF microscopy images of COS-1 cells co-expressing Flag-β2AR truncated at residue 341 (β2AR(341T), blue), β-arrestin-2-GFP (green) and clathrin light chain-DsRed (red) before and after treatment with 10 µM isoproterenol. b, Maximum β-arrestin-2-GFP enrichment at CCSs in cells treated with 10 µM isoproterenol and co-expressing the indicated Flag-β2AR construct. n = 11 cells from three independent experiments; P = 0.5634, twotailed unpaired t-test. NS, not significant. c, Live-cell TIRF microscopy images showing Flag-DRD2 G protein-biased mutant (DRD2(G prot), blue), β-arrestin-2-GFP (green) and clathrin light chain-DsRed (red) before and after treatment with 10 µM quinpirole. d, Mean (±s.e.m.) enrichment of β-arrestin-2-GFP in CCSs as shown in c. Green, wild-type (WT) Flag-DRD2; grey, Flag-DRD2(G prot). e, Maximum enrichment of β-arrestin-2-GFP in CCSs of cells as shown in c treated with 10 µM quinpirole. In d and e, n = 11 (wild-type) and 14 (G protein-biased) cells from three independent experiments; P = 0.013, two-tailed unpaired t-test using Welch's correction. a and c show representative images from three independent experiments. Scatter plots show overlay of mean and s.e.m. Scale bars, 5 µm. *P < 0.05.
Article reSeArcH β-arrestin-2) but there is no obvious binding partner for K77 (K78 in β-arrestin-2), even though point mutation of this residue produced the strongest constitutive phenotype. We used molecular dynamics simulations to identify acidic residues that might interact with K77. In inactive-state simulations, K77 sometimes formed an intramolecular salt bridge with E313 in the C domain, but this interaction rarely formed in active-state simulations (Fig. 3d, Extended Data Fig. 5b ). This interaction may have been overlooked previously because E313 interacts with R188 on another β-arrestin molecule in the crystal lattice, probably owing to lattice packing (Extended Data Fig. 5c ). Both K77 and E313 are conserved in β-arrestin-2 (K78 and E314, Extended Data Fig. 5d ) and, in both β-arrestin isoforms, separation of N and C domains is thought to accompany β-arrestin activation 20, 29, 30 . Therefore we hypothesized that K77/78 and E313/314 occasionally form a salt bridge that stabilizes the inactive state of β-arrestin by favouring tighter interactions between the N and C domains. Charge mutation of E314 (E314K) also produced ligand-independent accumulation of β-arrestin-2 in CCSs (Fig. 3e) . Further, mutating both residues (K78E/E314K) to restore the putative ionic interaction by charge swap reversed this constitutive phenotype (Fig. 3e) . Together, these findings suggest that the finger-loop-proximal charged residues function as part of an inter-domain interaction network that maintains β-arrestin in its inactive cytoplasmic form and is destabilized by interaction with the GPCR core.
Capture after GPCR dissociation
For β-arrestin to traffic to CCSs after dissociating from its upstream activating GPCR, additional partner(s) must engage and stabilize β-arrestin at the plasma membrane. We focused on several known candidates (Extended Data Table 1 , Extended Data Fig. 6a, b) . Mutating a conserved phosphoinositide binding determinant in the β-arrestin C domain that was previously mapped and implicated in β-arrestin trafficking 31 prevented ligand-induced accumulation of β-arrestin-2 at the plasma membrane and in CCSs (lipid mutant, Fig. 4a -i, Extended Data Fig. 6c, d ). We demonstrated biochemically that binding of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P 2 ) to this determinant is sufficient to partition β-arrestin out of the solution phase (Extended Data Fig. 6e, f) . This phosphoinositide-binding determinant is specific to β-arrestins, but a lipid-anchoring region in the C domain was recently identified in visual arrestin (also known as arrestin-1) 32 . Mutating the homologous residues in β-arrestin-2 did not prevent accumulation at the plasma membrane or in CCSs (Extended Data Table 1, Extended Data Fig. 6g, h ). Mutating previously identified clathrin 33 and AP-2 34 binding determinants (CCS mutant) in the C terminus of β-arrestin prevented β-arrestin-2 from accumulating in CCSs without blocking accumulation at the plasma membrane (Extended Data Table 1 , Fig. 4j -l, Extended Data Fig. 6i ). Mutating the phosphoinositide binding determinant together with clathrin and AP-2 binding determinants blocked β-arrestin-2 accumulation at the plasma membrane altogether, the same phenotype that resulted from mutating only the phosphoinositide binding determinant (lipid and CCS mutant, Fig. 4m -o, Extended Data Fig. 6j ). Similar results were obtained using the β1AR rather than β2AR as the activating GPCR (Extended Data Fig. 6k-ac) . Further, mutating the phosphoinositide binding determinant prevented the constitutive trafficking phenotype produced by finger-loop-proximal charge mutations in β-arrestin-2 (Extended Data Fig. 6ad , ae). These results indicate that β-arrestin is stabilized at the plasma membrane after dissociating from its activating GPCR through a series of non-GPCR interactions. Whereas the phosphoinositide binding determinant was essential for β1AR-or β2AR-dependent trafficking of β-arrestin-2 to CCSs, it was not required for accumulation of β-arrestin-2 in CCSs produced by a chimaeric construct of β2AR containing the tail region of the V2 vasopressin receptor (β2AR-V2R chimaera), a GPCR that is known to form a highly stable tail-dependent GPCR-β-arrestin scaffold complex 35 (Extended Data Fig. 7a-c) . Independently verifying this difference, depleting PtdIns(4,5)P 2 from the plasma membrane using phenylarsine oxide (PAO) 36 blocked the ability of β2AR but not that of the β2AR-V2R chimaera to activate trafficking of wild-type β-arrestin-2 to CCSs (Extended Data Fig. 7d-g ). Thus, phosphoinositide binding to β-arrestin appears to be required specifically for trafficking of β-arrestin to CCSs after it dissociates from its upstream activating GPCR, but not for trafficking to CCSs while bound in a sufficiently stable GPCR-β-arrestin scaffold complex.
Dynamics in the plasma membrane
We next investigated the discrete trafficking mechanism using single-particle tracking-photoactivated localization microscopy or β-arrestin-1-mVenus (c) constructs without agonist treatment. n = 12 cells from three independent experiments; P < 0.0001 and 0.0008, respectively, two-tailed unpaired t-test. d, Snapshot from molecular dynamics simulations of inactive-state β-arrestin-1 in which K77 and E313 occasionally form a stable salt bridge. This salt bridge formed 6% of the time in inactivestate simulations (six simulations, total duration = 26.7 µs); it may form more frequently on longer timescales. It formed in only a few frames of active-state simulations (0.2% of the time across six simulations, total duration = 29.3 µs). e, Clustering index of the indicated β-arrestin-2-GFP construct without agonist treatment. Statistics were calculated using a two-tailed unpaired t-test. For K78E, n = 12 cells from three independent experiments, P = 0.0003; for E314K, n = 12 cells from three independent experiments, P < 0.0001. Scatter plots show overlay of mean and s.e.m. Scale bars, 5 µm. ***P < 0.001.
Article reSeArcH (sptPALM 37 , Fig. 5a -d, Extended Data Fig. 8a -e, Supplementary Videos 1-4). β-arrestin-2 diffusion profiles exhibited two major peaks when activated by the β2AR. A mobile fraction (D > 10 −2 µm 2 s −1 ; log D > −2) overlapped the major diffusion peak of the β2AR, and also that of a lipid probe (PH-PLCδ1) that is known to diffuse freely in the plasma membrane 38 ( Fig. 5e , Extended Data Fig. 8f-h ). An immobile fraction (D ≤ 10 −2 µm 2 s −1 ; log D ≤ −2), consistent with the mobility of CCSs was also observed 39 , and the density of immobile β-arrestin-2 molecules was significantly higher within a CCS mask compared to the rest of the plasma membrane. This was true irrespective of whether β-arrestin-2 trafficking was activated by the β1AR or β2AR (9.3 and 6.0-fold enrichment, respectively; n = 11 and 9 cells, respectively, from three independent experiments; P = 0.0004 and 0.0016, respectively; statistical significance calculated using a twotailed unpaired t-test). Destabilizing clathrin and AP-2 interactions using the β-arrestin-2 CCS mutant shifted the distribution into the mobile peak, irrespective of whether β-arrestin-2 recruitment was activated by the β1AR or β2AR (Fig. 5f , g, Extended Data Fig. 8i -l, Supplementary Videos 5, 6), confirming that the immobile fraction of β-arrestin-2 molecules largely represents those bound to the CCS lattice. This suggests that disrupting CCS binding displaces β-arrestin towards an association with a diffusive partner on the plasma membrane. Consistent with this, β-arrestin-2 molecules present within CCSs were essentially immobile after activation by either the β1AR or β2AR (log D = −2.3 and −2.7, respectively; Extended Data Fig. 8m-p) . Trajectories of both β1AR and β2AR populated CCSs, but β2ARs were preferentially immobilized (log D = −2.3) there, whereas β1ARs remained largely mobile (log D = −1.6). Together, these results indicate that β-arrestin is similarly immobilized in CCSs irrespective of whether (β2AR) or not (β1AR) the activating GPCR is also immobilized there.
Stability of β-arrestin capture
Our results support a working model in which the ligand-activated GPCR acts catalytically to activate β-arrestin trafficking (Extended Data Fig. 8q ). β-arrestin is subsequently captured and stabilized at the plasma membrane after dissociating from its activating GPCR through a series of non-GPCR interactions that ultimately produce β-arrestin accumulation at CCSs. For this discrete mechanism to be energetically feasible, these non-GPCR interactions must be relatively stable. Indeed, fluorescence recovery after photobleaching (FRAP) demonstrated that β-arrestin-2 accumulated in CCSs exchanges very slowly (half time of equilibrium, t 1/2 > 60 s), whether (β2AR) or not (β1AR) the GPCR stimulating β-arrestin accumulation in CCSs co-accumulated (Fig. 5h-j , Extended Data Fig. 8r) . Notably, this duration of β-arrestin association with the CCS is comparable to the lifetime of individual CCSs 18 . Thus CCSs have the capacity to act both as 'sinks' to stabilize β-arrestin at the plasma membrane after GPCR dissociation and as 'drivers' of the discrete trafficking mechanism through β-arrestin dissociation from the plasma membrane coupled to endocytic scission of CCSs 18 .
Catalysis and scaffolding co-exist
We believe that distinct catalytic and scaffold-driven mechanisms of GPCR-regulated β-arrestin trafficking are likely to coexist in vivo, with the tendency of a particular GPCR to engage one mechanism relative to the other tuned by the affinity of its tail for β-arrestin (Extended Data Fig. 9a) . The β1AR appears to be a relatively pure example of a GPCR that activates β-arrestin trafficking primarily through the catalytic mechanism and with very little co-trafficking. The β2AR-V2R chimaera favours co-trafficking in a tail-dependent scaffold complex, with trafficking of β-arrestin to CCSs not requiring phosphoinositide binding. The β2AR has a mixed trafficking behaviour, producing super-stoichiometric trafficking of β-arrestin to CCSs that is Wild-type β-arrestin-2-GFP maximum enrichment in k and n is replotted from data shown in e. PM, plasma membrane. Statistics were calculated using a two-tailed unpaired t-test with Welch's correction. In h, n = 12 and 11 cells, respectively, from three independent experiments, P = 0.0006. In k, n = 10 cells from three independent experiments, P = 0.0102. In n, n = 10 cells from three independent experiments, P = 0.0022. β-arrestin mutations are described in detail in Extended Data Table 1 . Scatter plots show overlay of mean and s.e.m. Scale bars, 5 µm. **P < 0.01; ***P < 0.001.
Article reSeArcH dependent on phosphoinositide binding, yet also co-trafficking to CCSs through interaction of the phosphorylated receptor tail with β-arrestin.
Manipulations that enhance GPCR tail binding to β-arrestin are able to further increase β2AR co-trafficking to CCSs and also cause β1AR to co-traffic (Extended Data Fig. 9b -e), emphasizing the tunability of this system.
Discussion
These results reveal a new framework of cellular β-arrestin activation but raise many additional questions. One is whether catalytic activation of β-arrestin produces a similar or different conformational state relative to β-arrestin that traffics in a tail-dependent GPCR-β-arrestin scaffold complex. Tail-dependent GPCR-β-arrestin complex formation is thought to promote an open β-arrestin conformation defined by displacement of the C terminus of β-arrestin. Determinants of binding to clathrin and AP-2 that are required for β-arrestin accumulation in CCSs are located in the C terminus; therefore, β-arrestin that accumulates in CCSs via the catalytic activation mechanism is likely to be in an open conformation. However, it is not known whether other conformational features of β-arrestin are similar or different between the mechanisms. The accompanying Letter by Latorraca et al. 40 provides insight into this question by demonstrating through molecular dynamics analysis not only that the GPCR core can promote conformational activation of arrestins, but also that arrestins can frequent conformations similar to those found in the GPCR tailbound complex once the arrestin C terminus is dissociated, even without the GPCR being bound. Another important goal is to more fully resolve individual steps in the catalytic activation mechanism and determine their kinetics. For example, β-arrestin trafficking could involve additional steps such as transactivation or binding to the phosphorylated tail of another GPCR. Much also remains unknown about the functional consequences of GPCR-catalysed β-arrestin trafficking. β1ARs are known to promote β-arrestin-dependent ERK signalling by activating β-arrestin trafficking to CCSs without the receptor 18 ; we verified this using a CRISPR knockout approach 41 (Extended Data Fig. 9f, g ). The β2AR is unlike the β1AR in that it has a tendency to co-traffic to CCSs with β-arrestin; and β2AR did not produce a strong β-arrestin-dependent component of ERK activation using this assay, when examined in parallel and with matched receptor expression levels (Extended Data Fig. 9h , i). Therefore we anticipate that the presently delineated catalytic mechanism of cellular β-arrestin activation, by enabling β-arrestin to traffic to CCSs separately from its upstream activating GPCR, is likely to have widespread physiological significance.
Online content
Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0079-1. . β-arrestin-2-PAmCherry and PAmCherry-PLCδ1-PH were co-expressed individually with Flag-β2AR. PLCδ1-PH is the PH domain of phospholipase C δ1, which selectively binds to PtdIns(4,5)P 2 . f, g, False-positive-corrected distribution of diffusion coefficients of wild-type and CCS mutant β-arrestin-2-PAmCherry when co-expressed with Flag-β1AR (f; n = 13 and 17 cells, respectively, from three independent experiments; statistical significance of the immobile fractions was calculated using a two-tailed unpaired t-test, P < 0.0001) or Flag-β2AR (g; n = 21 and 10 cells, respectively, from three independent experiments; statistical significance of the immobile fractions was calculated using a two-tailed unpaired t-test, P = 0.002). β-arrestin-2-PAmCherry diffusion coefficient profiles when activated by the β2AR are replotted from e. h, COS-1 cells co-expressing Flag-β2AR, β-arrestin-2-GFP (green), and clathrin light chain-DsRed (red) were treated with 10 µM isoproterenol for 3 min before photobleaching of β-arrestin-2-GFP. Shown are representative images (from three independent experiments) of the photobleached area. β-arrestin-2 clustering index over the course of the photobleaching experiment in cells co-expressing activated Flag-β1AR (i; n = 12 cells from three independent experiments) or Flag-β2AR (j; n = 15 and 13 cells for unbleached and photobleached conditions, respectively, from three independent experiments). Data are mean ± s.e.m. Scale bars, 0.5 µm.
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MEthodS
Cell culture, expression constructs, and transfections. HEK 293, COS-1, and H9c2 cells (ATCC authenticated lines CRL-1573, CRL-1650 and CRL 1446, respectively) were cultured in complete growth Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (UCSF Cell Culture Facility). Cell line cultures were free of mycoplasma contamination. Transfections were carried out using Lipofectamine 2000 for cDNA according to the manufacturer's protocol. Cells were transfected 48 h before experiments.
N-terminally Flag-tagged versions of the human β1AR, β2AR, µ-opioid receptor (MOR) and κ-opioid receptor (KOR) were previously described 42, 43 . Super ecliptic pHluorin-β2AR was previously described 44 . β1AR and β2AR tagged N-terminally with photoactivatable mCherry (PAmCherry-β1AR, PAmCherry-β2AR) was generated using PCR and homology-directed ligation (In-Fusion HD Cloning kit, Clontech). DRD2 was a gift from D. Grandy (Oregon Health & Science University). DRD2 (G prot) was prepared as previously described 27 by inserting a gBlock gene fragment (IDT) containing the desired mutations with restriction sites BamHI and BstEII (NEB) into the wild-type DRD2 plasmid. The β2AR-V2R chimaera 45 was a gift from M. Caron. β1AR-β2AR C tail, β1AR-V2R C tail, β2AR-β1AR C tail were generated using PCR and homology-directed ligation (In-Fusion HD Cloning kit, Clontech). N-terminally Flag-tagged β1AR(415T) was generated from Flag-β1AR using site-directed mutagenesis (Phusion Site-Directed Mutagenesis Kit, Thermo Scientific) to create a deletion after residue 415. N-terminally Flag-tagged β2AR(341T) and Flag-tagged β2AR(365T), which were previously described 46, 47 , were prepared by PCR site-directed mutagenesis (Phusion Site-Directed Mutagenesis Kit, Thermo Scientific). β2AR with an N-terminal Flag tag and a C-terminal GFP tag was generated by inserting a gBlock (IDT) containing a C-terminal fragment of β2AR, a 12 base pair linker and GFP using EcoRV and PshAI (NEB).
β-arrestin-2-GFP, β-arrestin-2-mApple and β-arrestin-2-PAmCherry were previously described 17, 18 . β-arrestin-1-mVenus was a gift from R. Sunahara (University of California, San Diego). Specific β-arrestin-2-GFP mutations are described in detail in Extended Data Table 1 . All β-arrestin-2-GFP fingerloop-proximal mutants were created by inserting a gBlock (IDT) containing the desired mutations into the β-arrestin-2-GFP wild-type plasmid using restriction sites HindIII and BbvCI (NEB). β-arrestin-2-GFP(E314K) and β-arrestin-2-GFP (K77E/E314K) were created using site-directed mutagenesis (Phusion Site-Directed Mutagenesis Kit, Thermo Scientific) from the wild-type β-arrestin-2-GFP or β-arrestin-2-GFP (K77E) construct, respectively. β-arrestin-2-GFP lipid-binding mutant was previously described 31 and was created by inserting a gBlock (IDT) containing the desired mutations into the β-arrestin-2-GFP wild-type plasmid using restriction sites BbvCI and AhdI (NEB). β-arrestin-2-GFP CCS mutant and β-arrestin-2-PAmCherry CCS mutant were created by inserting a gBlock (IDT) containing the desired mutations into the β-arrestin-2-GFP and β-arrestin-2-PAmCherry plasmids, respectively, using restriction sites BlpI and ApaI (NEB). β-arrestin-2-GFP lipid and CCS mutant and β-arrestin-2-GFP lipid and finger-loop-proximal mutant constructs were created by inserting a gBlock (IDT) containing the desired mutations into the β-arrestin-2-GFP CCS mutant plasmid and β-arrestin-2-GFP finger-loop-proximal mutant construct, respectively, using restriction sites BbvCI and AhdI (NEB). β-arrestin-2-GFP(L191G/F192G) was created using site-directed mutagenesis (Phusion Site-Directed Mutagenesis Kit, Thermo Scientific) from the wildtype β-arrestin-2-GFP. β-arrestin-1-mVenus finger-loop-proximal mutant was cloned by inserting a gBlock (IDT) containing the desired mutation into the β-arrestin-1-mVenus wild-type plasmid using restriction sites BamHI and SphI (NEB). β-arrestin-2-GFP KNC mutant, which has been previously described and shown to be defective in binding to GPCRs 25 , was subcloned into β-arrestin-2-GFP from a β-arrestin-2 expression plasmid (a gift from V. Gurevich). NAV3β-arrestin-1(1-393) in pGEX4T was generated from a previously described construct 23 and contains an N-terminal GST tag, 3C cleavage site and AVI tag. NAV3β-arrestin-1(1-393) lipid-binding mutant was created by inserting a gBlock (IDT) containing the desired mutations into the NAV3β-arrestin-1(1-393) using restriction sites EcoRI and NcoI (NEB).
Clathrin-dsRed, clathrin-GFP and clathrin-TagBFP were previously described 15, 18, 48 . GRK2-tagBFP was created by PCR amplifying GRK2, which was a gift from J. Benovic (Thomas Jefferson University), and subcloning into the pTagBFP vector (Evrogen) using NheI and SacII (NEB). PAmCherry-PLCδ1-PH was subcloned from GFP-PLCδ1-PH 49 , a gift from T. Meyer (addgene plasmid #21179), using BspEI and EcoRI (NEB). Live cell TIRF microscopy imaging. TIRF microscopy was performed at 37 °C using a Nikon Ti-E inverted microscope equipped for through-the-objective TIRF microscopy and outfitted with a temperature-, humidity-and CO2-controlled chamber (Okolab). Images were obtained with an Apo TIRF 100 × , 1.49 numerical aperture objective (Nikon) with solid-state 405, 488, 561 and 647 nm lasers (Keysight Technologies). An Andor iXon DU897 EMCCD camera controlled by NIS-Elements 4.1 software was used to acquire image sequences every 2 s for 10 min. Unless indicated otherwise, live-cell microscopy assays were performed using HEK 293 cells. Cells were transfected as indicated according to the manufacturer's protocol 48 h before imaging and then plated on poly-l-lysine (0.0001%, Sigma) coated 35-mm glass-bottomed culture dishes (MatTek Corporation) 24 h before imaging. Cells were labelled with monoclonal Flag antibody (M1) (1:1000, Sigma F-3040) conjugated to Alexa Fluor 647 dye (Life Technologies) for 10 min at 37 °C before imaging, washed, and imaged live in DMEM without phenol red (UCSF Cell Culture Facility) supplemented with 30 mM HEPES, pH 7.4 (UCSF Cell Culture Facility). Cells were treated with bath application of the indicated agonist at time 0 s for experiments shown as timecourses. At least three independent experiments were performed for all live-cell TIRF microscopy imaging. TIRF microscopy image analysis. Quantitative image analysis was performed on unprocessed images using ImageJ and Fiji software 50, 51 . To quantify change in β-arrestin fluorescence over time in TIRF microscopy images, which was reported as plasma membrane recruitment, fluorescence values were measured over the entire stack in a region of interest (ROI) corresponding to the cell. Fluorescence values of the ROI were normalized to initial fluorescence values before agonist addition. Minimal bleed-through and photobleaching was verified using singlelabelled and untreated samples, respectively. Linescan analysis of receptor, β-arrestin, or clathrin fluorescence from the shown line were carried out using the Fiji plot profile function to measure pixel values from this line. For calculations of fluorescence enrichment into CCSs, a mask of CCSs was generated using a thresholded average image of the clathrin channel. Enrichment at CCSs for receptor and arrestin was measured as the difference between the average fluorescence in the mask and average fluorescence outside of the thresholded structures. Clustering index was determined using the skew statistical measurement applied to fluorescence intensity values of β-arrestin-GFP pixels in a ROI corresponding to the cell. Fluorescence recovery after photobleaching. FRAP was performed at 37 °C using a Nikon Ti inverted spinning disk confocal microscope (Yokogawa CSU-W1) equipped with a temperature-, humidity-and CO2-controlled chamber (Okolab). Images were obtained with a Plan Apo VC 100 × , 1.4 NA objective (Nikon) with 488-, 561-and 640-nm solid-state lasers (Keysight Technologies). An Andor Zyla 4.2 sCMOS camera controlled by MicroManager 2.0 software was used to acquire image sequences. A Rapp Optoelectronic UGA-40 photobleaching system was used to photobleach β-arrestin-2-GFP on a small area of the plasma membrane with a 473-nm laser (Vortran). Cells were imaged every 2 s for 10 min to monitor fluorescence recovery after photobleaching. All quantitative image analysis was performed on unprocessed images using ImageJ software. The clustering index was calculated for the photobleached and unbleached areas of identical size in the same cell. Photobleaching experiments were performed at least three independent times. Quantitative live-cell sptPALM. Cells were transfected as indicated according to the manufacturer's protocol 48 h before imaging and then plated on poly-llysine (0.0001%, Sigma) coated 35-mm glass-bottomed culture dishes (MatTek Corporation) 24 h before imaging. Results were obtained with at least three independent experiments, except for the analysis of PAmCherry-β1AR diffusion coefficients profile. For experiments to investigate the diffusion coefficient profile of PAmCherry-tagged receptors, lipid sensor, β-arrestin-2 or control cells without PAmCherry protein expression, cells were surface-labelled with M1-Alexa Fluor 488 and experiments were performed blind regarding the transfection condition. For experiments to localize receptors or β-arrestin behaviour relative to CCSs, cells were incubated for 10 min with 100-nm TetraSpeck microspheres (ThermoFisher) and imaging was performed blind regarding transfection condition. sptPALM experiments were performed at 37 °C using a Nikon Ti-E inverted microscope equipped with TIRF illumination and outfitted with a temperature-, humidityand CO2-controlled chamber (Okolab). Cells were imaged in a solution containing 135 mM NaCl, 5 mM KCl, 0.4 mM MgCl 2 ,1.8 mM CaCl 2 , 20 mM HEPES and 5 mM d-glucose, adjusted to pH 7.4, 1 min after addition of 10 µM isoproterenol. Images were acquired with a PL-Apo TIRF 100 × , 1.49 NA objective (Nikon) with solid-state 405-, 488-, 561-and 647-nm lasers (Keysight Technologies) as light sources. An Andor iXon DU897 EMCCD camera controlled by NIS-Elements 4.1 software was used to acquire stacks of 5,000 images with continuous activation by 405-nm light and imaging by 561-nm laser. Single-molecule image sequences were acquired in streaming mode at 45 Hz in a 256 × 256-pixel area (40 × 40-µm field of view). For colocalization experiments, a clathrin-GFP image was aquired at the end of the sptPALM image series.
Single-molecule fluorescent spots were localized and tracked over time using a combination of wavelet-based segmentation and simulated-annealing tracking algorithms as previously described 52, 53 . The software package used to derive quantitative data on protein localization and dynamics is custom written, operating as a plug-in running within the MetaMorph software (Molecular Devices) environment. The mean square displacement (MSD) and diffusion coefficient (D) were calculated for every trajectory as follows. For every trajectory of N data points Article reSeArcH (coordinates x(t), y(t) at times t = 0 to NΔt with Δt = 22 ms), the mean square displacement (MSD) for time intervals τ = n × Δt is calculated using the formula . To define the diffusion profile across the different conditions, we included only trajectories longer than six points. To take into account false detections due to non-specific single-molecule signals, we computed an average histogram of diffusion coefficients from trajectories obtained by imaging cells without PAmCherry expression, using the same parameters described previously. The variability of the number of localizations and diffusion profiles of non-specific single-molecule signal was very low. For each cell exhibiting at least five times more trajectories than the average false-detection count, the histogram of false detections was subtracted from the distribution of diffusion coefficients. Histograms of diffusion coefficients were computed by normalizing the number of trajectories for each bin by the total number of trajectories after false-detection subtraction. We considered trajectories with D ≤ 10 −2 µm 2 s −1 as immobile and used this criterion for evaluation of statistical significance using a two-tailed t-test.
For analysis of localization of trajectories relative to CCPs, single-particle tracking movies as well as diffraction limited clathrin-GFP images were aligned with subpixel accuracy using a Gaussian fitting on the Tetraspeck microsphere signal as fiduciary marker. Trajectories of more than eight points were used to generate the super-resolution images with a pixel size of 19.6 nm (zoom 8 × compared to the acquired data) and compute the diffusion coefficients as described above. A series of super-resolution images was generated displaying reconstructed individual trajectories, localization density of mobile molecules (D ≥ 10 −2 µm 2 s
), or diffusion coefficient maps. Diffusion coefficient maps were computed by averaging in each pixel the diffusion coefficients from all the trajectories detected in the corresponding pixel. Images of CCSs were zoomed 8 × before alignment and overlaid with the super-resolution images. A binary mask of the CCSs was generated using ImageJ (NIH) by thresholding and eroding by two pixels the 8 × zoomed image of the clathrin mask after bandpass filtering in the Fourier domain. This mask was used in combination with the super-resolution images to calculate the average diffusion coefficient as well as the density of localization with respect to the CCSs. ERK1/2 activation assays. Western blot analysis was used to measure activation of ERK1/2. Previously described parental HEK 293 and β-arrestin CRISPR knockout HEK 293 cell lines 41 were transfected with empty vector control, Flag-β1AR or Flag-β2AR expression constructs. Cells were serum starved for 18 h before the assay, incubated with 10 µM isoproterenol for the indicated times at 37 °C, and then washed on ice with ice-cold PBS. Cells were directly lysed in sample buffer (NuPAGE LDS Sample Buffer (Life Technologies), 100 mM dithiothreitol), sonicated three times for 10 s, boiled, separated by SDS-PAGE (Life Technologies) and transferred to a nitrocellulose membrane that was blocked with TBS Odyssey blocking buffer (LI-COR) for one hour at room temperature and then incubated overnight at 4 °C with a mouse ERK1/2 primary antibody (1:2,000, Cell Signaling 4696) and a rabbit phosphorylated-ERK1/2 primary antibody (1:2,000, Cell Signaling 4370). Membranes were washed three times for 5 min in TBS-Tween (0.1% v/v) and incubated with a IRDye 680-labelled anti-rabbit secondary antibody (1:5,000, LI-COR 926-68073) and an IRDye 800-labelled anti-mouse secondary antibody (1:5,000, LI-COR 926-32212) for one hour at room temperature. Membranes were washed three times for 5 min in TBS-Tween (0.1% v/v), imaged using an Odyssey Infrared Imaging System (LI-COR) in the linear range and quantified by measuring band intensity, background subtracting, and normalizing the phosphorylated ERK1/2 band intensity to the total ERK1/2 band intensity. Data are shown as fraction of the maximum response observed across all conditions in each experiment. Five independent experiments were performed for each condition. Co-immunoprecipitation. Cells expressing indicated constructs were grown to confluency in 10-cm dishes, and 48 h after transfection, cells were washed twice with reaction buffer (PBS, 30 mM HEPES, pH 7.4) and then crosslinked with 2 mM DSP (Thermo Scientific) for 30 min at room temperature with gentle agitation. The crosslinking reaction was stopped by addition of 20 mM Tris, pH 7.5 for 15 min. Cells were collected, pelleted by centrifugation, lysed on ice for 10 min in 500 µl ice-cold lysis buffer (0.2% Triton X-100, 150 mM NaCl, 25 mM KCl, 10 mM Tris pH 7.4, and 1 mM EDTA supplemented with a standard protease inhibitor mixture (Roche Applied Science)) and then cleared by centrifugation (14,000g for 15 min at 4 °C).
Samples were incubated overnight at 4 °C with anti-GFP antibody covalently linked to sepharose beads (1:3, Abcam ab69314), washed with lysis buffer three times, and incubated with SDS sample buffer (Invitrogen) supplemented with 100 mM dithiothreitol to elute proteins. Samples were then separated by SDS-PAGE (Life Technologies) and transferred to a nitrocellulose membrane that was blocked with TBS Odyssey blocking buffer (LI-COR) for one hour at room temperature and then incubated overnight at 4 °C with a mouse β-adaptin primary antibody (1:250, BD Biosciences 610382) and a rabbit GFP primary antibody (1:500, Thermo Fisher Scientific A-11122). Membranes were washed three times for 5 min in TBS-Tween (0.1% v/v) and incubated with an IRDye 680-labelled anti-rabbit secondary antibody (1:5,000, LI-COR 926-68073) and an IRDye 800-labelled antimouse secondary antibody (1:5,000, LI-COR 926-32212) for one hour at room temperature. Membranes were washed three times for 5 min in TBS-Tween (0.1% v/v), imaged using an Odyssey Infrared Imaging System (LI-COR) in the linear range and quantified by measuring band intensity, background subtracting, and normalizing the AP-2-immunoprecipitated band intensity to the GFP-bead band intensity. Three independent experiments were performed. Purification of β-arrestin-1. N-terminally GST-tagged rat β-arrestin-1 (amino acids 1-393) constructs in the pGEX4T vector were transformed into BL21-CodonPlus(DE3)-RIPL cells (Agilent). Cultures were grown at 37 °C to an absorbance (A 600 nm ) of 0.6 in Terrific broth and then equilibrated to 16 °C. GST-β-arrestin-1 expression was induced with 0.1 mM isopropyl 1-thio-β-d-galactopyranoside overnight at this temperature, and cells were collected by centrifugation at 6,000g. Pellets were resuspended with cold lysis buffer (50 mM HEPES pH 8.2, 150 mM NaCl, 2 mM DTT, protease inhibitors, 1 mM EDTA). Cells were lysed by passage through an Emulsiflex press (Avestin) and cleared by centrifugation at 40,000g for 50 min. The clarified supernatant was incubated with GST-4B resin (GE Healthcare) for 2 h at 4 °C, and then washed two times with five column volumes of wash buffer (50 mM HEPES pH7.4, 150 mM NaCl, 2 mM DTT). The GST resin with bound GST-β-arrestin-1 was resuspended in two column volumes of wash buffer, and the GST fusion protein was cleaved with 0.1 mg of 3C protease per ml of GST resin overnight at 4 °C. The supernatant and first wash fraction were pooled and centrifuged at 40,000g for 30 min. The cleared supernatant was filtered with a 0.45-µm filter, concentrated to 500 µl and gel-filtered using a Superose 6 10/300 gl column (GE Life Science). β-Arrestin-1 was eluted in gel filtration buffer (30 mM HEPES, 150 mM NaCl, 2 mM MgCl 2 , 5% glycerol). Fractions were analysed by SDS-PAGE and fractions containing β-arrestin-1 were pooled and concentrated, flash-frozen in liquid N 2 , and stored at −80 °C. Lipid-bead binding. Equal amounts of purified wild-type or lipid-binding mutant β-arrestin-1 protein were incubated with PtdIns(4,5)P 2 -coated beads (Echelon) for two hours at room temperature in wash/binding buffer (10 mM HEPES, pH 7.4, 0.25% NP-40, 150 mM NaCl). Samples were then washed three times with wash/ binding buffer. To elute proteins, equal volumes of 2 × Laemmli sample buffer were added and samples were incubated at 95 °C for 5 min. Samples were then separated by SDS-PAGE (Life Technologies) and transferred to a nitrocellulose membrane that was blocked with TBS Odyssey blocking buffer (LI-COR) for one hour at room temperature and then incubated for one hour at room temperature with a mouse anti-β-arrestin primary antibody (1:500, Santa Cruz Biotechnology sc-13140). Membranes were washed three times for 5 min in TBS-Tween (0.1% v/v) and incubated with an IRDye 800-labelled anti-mouse secondary antibody (1:5,000, LI-COR 926-32212) for one hour at room temperature. Membranes were washed three times for 5 min in TBS-Tween (0.1% v/v), imaged using an Odyssey Infrared Imaging System (LI-COR) in the linear range, and quantified by measuring band intensity and subtracting background intensity. Four independent experiments were performed. Molecular dynamics simulations. We analysed sets of molecular dynamics simulations for each of two conditions: (1) simulations initiated from the inactive-state β-arrestin-1 crystal structure (PDB ID: 1G4M, chain A), and (2) simulations initiated from the active-state β-arrestin-1 crystal structure bound to the phosphorylated C-tail of the V2 vasopressin receptor (PDB ID: 4JQI). For the latter condition, we removed the co-crystallized F ab 30 antibody fragment. We performed six simulations for each condition. For each simulation, initial atom velocities were assigned randomly and independently. These simulations correspond to simulations 40 to 51 in Supplementary Table 1 of the accompanying Letter   40 , which also provides details regarding simulation setup and simulation protocols.
Simulations were visualized and analysed using Visual Molecular Dynamics (VMD) 54 . Simulations were inspected visually for interactions that formed in the inactive state but not the active state. We noticed that Glu313 occasionally formed a salt bridge with Lys77 in the inactive state, persisting for up to hundreds of nanoseconds. We quantified the frequency of salt bridge formation by calculating the minimum distance between polar heavy atoms of Lys77 and Glu313 across all simulations under each condition. Statistical analysis. Quantitative data are expressed as the mean and error bars represent the standard error of the mean (s.e.m.) unless otherwise indicated. Scatter plots are overlaid with mean and s.e.m. Statistical significance between conditions was analysed using a two-tailed t-test or with Welch's correction for
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Extended Data Fig. 1 | Verification of GPCR-specificity of the discrete β-arrestin trafficking mechanism, demonstration that this mechanism produces super-stoichiometric β-arrestin accumulation in CCSs and that its activation does not require the GPCR tail. a, Mean β-arrestin-2-GFP enrichment at CCSs in cells expressing Flag-β1AR after the following treatments: 10 µM isoproterenol (green, n = 14 cells), 15-min pretreatment with 10 µM CGP 20712 A and treatment with 10 µM isoproterenol (red, n = 12 cells), or 10 µM CGP 20712 A alone (grey, n = 12 cells). Data shown for the 10 µM isoproterenol condition are replotted from Fig. 1b . b, Maximum β-arrestin-2-GFP enrichment at CCSs in HEK 293 cells transfected with the indicated receptor or empty vector and treated with 10 µM isoproterenol. c, β-arrestin-2-GFP enrichment at CCSs in H9c2 cells without GPCR overexpression and treated with 10 µM isoproterenol or 10 µM dobutamine (n = 5 or 4 cells, respectively, from two independent experiments). d, β-arrestin-2-GFP enrichment at CCSs in H9c2 cells without GPCR overexpression and treated as indicated (n = 12 cells). e, Live-cell TIRF microscopy images (representative of n = 3 independent experiments) showing Flag-β1AR (blue), β-arrestin-1-mVenus (green) and clathrin light chain-DsRed (red) before and after treatment with 10 µM isoproterenol. f, Enrichment into CCSs (n = 7 cells from three independent experiments). g, Maximum β-arrestin-1-mVenus enrichment at CCSs in HEK 293 cells transfected with Flag-β1AR or empty vector and treated with 10 µM isoproterenol (n = 7 and 11 cells, respectively, from three independent experiments; P = 0.0023 using an unpaired ttest with Welch's correction). h, Mean β-arrestin-2-GFP enrichment at CCSs in cells expressing Flag-β2AR after the following treatments: 10 µM isoproterenol (green, n = 15 cells), 15-min pretreatment with 10 µM ICI 118,551 and then treatment with 10 µM isoproterenol (red, n = 14 cells) or 10 µM ICI 118,551 (grey, n = 12). Data shown for the 10 µM isoproterenol condition are replotted from Fig. 1d . i, Fluorescence intensity profiles from lines shown in Fig. 1e . j, Time-dependent correlation coefficient of line scans across cells derived from immobilization experiments shown in Fig. 1e , f (n = 3). k, Live-cell TIRF microscopy images (representative of n = 3 independent experiments) showing Flag-β2AR-GFP and clathrin-lightchain-DsRed (red) before and after treatment with 10 µM isoproterenol. Fluorescence from the Alexa Fluor 647-conjugated Flag antibody shown in blue and GFP fluorescence shown in green. l, Difference in GFP and Alexa Fluor 647 fluorescence enrichment at CCSs in cells co-expressing Flag-β1ARs (red), Flag-β2ARs (blue) and β-arrestin-2-GFP or Flag-β2AR-GFP (black). Cells were labelled with Alexa Fluor 647-conjugated Flag antibody for 10 min before live-cell imaging. Data were derived from the experiments shown in Fig. 1a, b (blue line, n = 14 cells from three independent experiments), Fig. 1c, d (red line, n = 15 cells from three independent experiments) and Extended Data Fig. 1k (black line n = 12 cells from three independent experiments). m, Plot of β-arrestin-GPCR stoichiometry calculated from the data displayed in k, calibrated according to the double-labelled Flag-β2AR-GFP reference construct, which defines 1:1 stoichiometry (For β1AR and β2AR, n = 14 and 15 cells, respectively, from three independent experiments). A correction index was calculated by dividing GFP fluorescence by Alexa Fluor 647 (Flag) fluorescence in CCSs. This correction index was then applied to receptor and β-arrestin-2 enrichment in CCSs to determine β-arrestin-2-GPCR stoichiometry throughout the time course. Images were captured continuously at 0.5 Hz and stoichiometry values over the time course were calculated using a rolling average with 50-frame window size. Scale bar, 5 µm. Scatter plots show overlay of mean and s.e.m. a, d, h, l and l show data as mean ± s.e.m. **P < 0.01. Fig. 2 | Additional demonstration that multiple GPCRs can activate the discrete β-arrestin trafficking mechanism. a, Live-cell TIRF microscopy images showing Flag-MOR (blue), β-arrestin-2-GFP (green) and clathrin light chain-DsRed (red) before and after treatment with the opioid peptide DAMGO (10 µM). b, Mean Flag-MOR and β-arrestin-2-GFP enrichment at CCSs after treatment with 10 µM DAMGO (n = 12 cells). c, Maximum β-arrestin-2-GFP enrichment at CCSs for HEK 293 cells expressing Flag-MOR or empty vector and treated with 10 µM DAMGO (n = 12 cells per condition from three independent experiments; P < 0.0001 using a two-tailed unpaired t-test with Welch's correction). d, Live-cell TIRF microscopy images showing Flag-KOR (blue), β-arrestin-2-GFP (green) and clathrin light chain-DsRed (red) before and after treatment with 10 µM dynorphin. e, Enrichment into CCSs after bath application of 10 µM dynorphin (n = 18 cells). f, Maximum β-arrestin-2-GFP enrichment at CCSs in HEK 293 cells expressing Flag-KOR or empty vector and treated with 10 µM dynorphin (n = 18 and 13 cells, respectively, from three independent experiments; P = 0.0028 using a two-tailed unpaired t-test with Welch's correction). g, Live-cell TIRF microscopy images showing Flag-DRD2 (blue), β-arrestin-2-GFP (green) and clathrin light chain-DsRed (red), before and after treatment with 10 µM quinpirole. h, Enrichment into CCSs after bath application of 10 µM quinpirole (n = 12 cells). i, Maximum β-arrestin-2-GFP enrichment at CCSs in cells expressing Flag-DRD2 or untransfected and treated with 10 µM quinpirole (n = 11 and 12 cells from three independent experiments; P = 0.0095 using a two-tailed unpaired t-test with Welch's correction). a, d and g show representative images from three independent experiments. b, e and h show mean ± s.e.m. Scatter plots show overlay of mean and s.e.m. Scale bars, 5 µm. *P < 0.05; **P < 0.01; ***P < 0.001.
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Extended Data Fig. 3 | Direct interaction with the GPCR, but not  the GPCR cytoplasmic tail, is required for activation of β-arrestin  trafficking. a, Live-cell TIRF microscopy images showing Flag-β1AR(415T) (blue), β-arrestin-2-GFP (green) and clathrin light chain-DsRed (red) before and after treatment with 10 µM isoproterenol. b, Maximum β-arrestin-2-GFP enrichment at CCSs after treatment with 10 µM isoproterenol for cells co-expressing the indicated Flag-β1AR receptor (n = 10 and 12 cells, respectively, from three independent experiments; P = 0.5825 calculated using a two-tailed unpaired t-test). c, Live-cell TIRF microscopy images showing Flag-β2AR(365T) (blue), β-arrestin-2-GFP (green) and clathrin light chain-DsRed (red) before and after treatment with 10 µM isoproterenol. d, Maximum β-arrestin-2-GFP enrichment at CCSs in HEK 293 cells treated with 10 µM isoproterenol and transfected with either Flag-β2AR or empty vector (n = 11 and 13 cells, respectively, from three independent experiments; P = 0.0269 calculated using a two-tailed unpaired t-test with Welch's correction). e, Maximum β-arrestin-2-GFP enrichment at CCSs for cells co-expressing the indicated Flag-β2AR receptor and treated with 10 µM isoproterenol (n = 12 cells from three independent experiments; P = 0.0606 calculated using a two-tailed unpaired t-test). f, Live-cell TIRF microscopy images showing Flag-DRD2 (blue), β-arrestin-2-GFP (green) and clathrin light chain-DsRed (red) before and after treatment with 10 µM quinpirole. g, h, Initial enrichment in CCSs before treatment with 10 µM quinpirole (g) and maximum enrichment after treatment with 10 µM quinpirole (h) (n = 12 cells from three independent experiments; P = 0.19 and 0.4873, respectively, using a two-tailed unpaired t-test). i, Live-cell TIRF microscopy images showing Flag-β1AR (blue), β-arrestin-2-GFP (green) and clathrin light chain-DsRed (red) before and after treatment with 5 µM forskolin (fsk). j, k, Initial enrichment in CCSs before treatment with 5 µM forskolin (j) and maximum enrichment after treatment with 5 µM forskolin (k) (n = 12 cells from three independent experiments; P = 0.6325 and 0.0971, respectively, using a two-tailed unpaired t-test). l, Live-cell TIRF microscopy images showing Flag-β2AR (blue), β-arrestin-2-GFP KNC mutant (green) and clathrin light chain-DsRed (red) before and after treatment with 10 µM isoproterenol. m, n, Initial enrichment in CCSs before treatment with 10 µM isoproterenol (m) and maximum enrichment after treatment with 10 µM isoproterenol (n) (n = 9 (wild-type) or 8 (KNC mutant) cells from three independent experiments; P = 0.6681(m) and P = 0.001 (n) using a two-tailed unpaired t-test with Welch's correction). a, c, f, i and l show representative images from three independent experiments. Scatter plots show overlay of mean and s.e.m. Scale bars, 5 µm. *P < 0.05, **P < 0.01.
Extended Data Fig. 4 | Additional verification that charge mutations  in the finger-loop-proximal region of β-arrestin produce a constitutive activation phenotype. a, Live-cell TIRF microscopy images showing Flag-β2AR, clathrin light chain-DsRed (red) and the polar core mutant of β-arrestin-2-GFP (green) in the absence of agonist treatment. b, Clustering index of β-arrestin-2-GFP for the indicated construct in the absence of agonist treatment. Statistical significance was calculated using a two-tailed unpaired t-test with Welch's correction (polar core mutant: n = 12 cells from three independent experiments, P < 0.0001; fingerloop-proximal mutant: n = 16 cells from three independent experiments, P < 0.0001; R77A: n = 12 cells from three independent experiments, P = 0.0403; K78A: n = 12 cells from three independent experiments, P = 0.0016). Wild-type and finger-loop-proximal mutant data is replotted from Fig. 3b . c, Association of β-arrestin-2-GFP constructs with the β-adaptin subunit of AP-2 in the absence of agonist treatment. Molecular mass markers (in kDa) are shown on the right side of blots. For gel source data, see Supplementary Fig. 1 . The western blots in c are representative of three independent experiments, quantified in d, and shown as AP-2/GFP intensity in the immunoprecipitation conditions (n = 3 independent experiments, P = 0.0218 using a two-tailed unpaired t-test). e, β-arrestin-2-GFP expression in cell lysates from c. f-i, Live-cell TIRF microscopy images showing Flag-β2AR, clathrin light chain-DsRed (red) and β-arrestin-2-GFP with the indicated point mutations (green) in the absence of agonist treatment. Detailed descriptions of β-arrestin mutations are provided in Extended Data Table 1 . a and f-i show representative images from three independent experiments. Scatter plots show overlay of mean and s.e.m. Scale bars, 5 µm. *P < 0.05, **P < 0.01, ***P < 0.001. Fig. 6 | Verification that the conserved phosphoinositide binding determinant in the β-arrestin C domain is specifically required for the catalytic trafficking mechanism and operates upstream of clathrin-and AP-2-binding interactions. a, b, Graphical representation of β-arrestin interaction domains without (a) and with (b) βAR activation by isoproterenol. c, Live-cell TIRF microscopy images showing Flag-β2AR (blue), β-arrestin-2-GFP (green) and clathrin light chain-DsRed (red) before and after treatment with 10 µM isoproterenol. d, Live-cell TIRF microscopy images showing Flag-β2AR (blue), β-arrestin-2-GFP lipid mutant (green) and clathrin light chain-DsRed (red) before and after treatment with 10 µM isoproterenol. e, Representative western blot (from four independent experiments) of purified wild-type and lipid mutant versions of β-arrestin-1(1-393) immunoprecipitation with PtdIns(4,5) P 2 -coated agarose beads and quantified in f as per cent of input protein (n = 4 independent experiments, P = 0.0142 using a two-tailed unpaired t-test). For gel source data, see Supplementary Fig. 1 . g, Live-cell TIRF microscopy images showing Flag-β2AR (blue), β-arrestin-2(F191G/ L192G)-GFP lipid anchor mutant (green), and clathrin light chain-DsRed (red) before and after treatment with 10 µM isoproterenol. h, Maximum β-arrestin-2-GFP enrichment at CCSs in cells expressing the indicated β-arrestin-2-GFP construct and treated with 10 µM isoproterenol (n = 12 cells from three independent experiments; P = 0.9227 calculated using a two-tailed unpaired t-test). i, Live-cell TIRF microscopy images showing Flag-β2AR (blue), β-arrestin-2-GFP CCS mutant (green) and clathrin light chain-DsRed (red) before and after treatment with 10 µM isoproterenol. j, Representative images of HEK 293 cells co-expressing Flag-β2AR (blue), β-arrestin-2-GFP lipid and CCS mutant (green) and clathrin light chain-DsRed (red) before and after treament with 10 µM isoproterenol. Representative β-arrestin images false coloured to indicate fluorescence intensity, maximum fluorescence enrichment at CCSs and normalized average plasma membrane (PM) β-arrestin-2-GFP fluorescence (mean ± s.e.m.), respectively, from cells co-expressing Flagβ1ARs (n = 12 cells per condition) without isoproterenol treatment (k-m), and the following β-arrestin-2-GFP constructs with treatment with 10 µM isoproterenol: wild-type (n-p), lipid mutant (q-s), CCS mutant (t-v) and CCS and lipid mutant (w-y). Wild-type β-arrestin-2-GFP maximum enrichment at CCSs shown in r, u and x is replotted from o. z-ac, Livecell TIRF microscopy images showing cells before and after treatment with 10 µM isoproterenol and co-expressing Flag-β1AR (blue), clathrin light chain-DsRed (red) and the following GFP-labelled versions of β-arrestin-2 (green): wild-type (z), lipid mutant (aa), CCS mutant (ab), and CCS and lipid mutant (ac). ad, Live-cell TIRF microscopy images showing Flag-β2AR and the indicated β-arrestin-2-GFP construct in the absence of agonist treatment. ae, Clustering index of β-arrestin-2-GFP for the indicated construct in the absence of agonist treatment. Detailed description of β-arrestin mutations are provided in Extended Data Table 1 . c, d, g, i-k, n, q, t, w and z-ad show representative images from three independent experiments. In r, u and x, n = 12 cells from three independent experiments; unpaired t-test with Welch's correction, P = 0.0007, 0.0018 and 0.0012, respectively. In ae, n = 12 (wild-type) and 16 (finger-loop-proximal mutant) from three independent experiments; unpaired t-test with Welch's correction, P < 0.0001; n = 12 (wild-type) and 15 (finger loop proximal & lipid mutant) from three independent experiments; P = 0.5464. Wild-type and finger-loop-proximal mutant data replotted from Fig. 3b . Scatter plots show overlay of mean and s.e.m. Scale bars, 5 µm. **P < 0.01, ***P < 0.001. Fig. 7 | Phosphoinositide binding is essential for catalytic activation of β-arrestin trafficking but is dispensable for trafficking mediated by the scaffold mechanism. a, Live-cell microscopy images of HEK 293 cells co-expressing Flag-β2AR-V2R C tail (blue), β-arrestin-2-GFP CCS mutant (green) and clathrin light chain-DsRed (red) before and after treatment with 10 µM isoproterenol. b, Normalized plasma membrane fluorescence of β-arrestin-2-GFP lipid mutant in cells co-expressing Flag-β2AR-V2R (n = 12 cells from three independent experiments) when treated with 10 µM isoproterenol. c, Maximum β-arrestin-2-GFP enrichment at CCSs in cells expressing indicated β-arrestin-2-GFP before and after activation of Flag-β2AR-V2R chimaera with 10 µM isoproterenol (n = 10 and 12 cells, respectively, from three independent experiments; P = 0.6433, two-tailed unpaired t-test). d, Livecell microscopy images of COS-1 cells co-expressing Flag-β2AR (blue), β-arrestin-2-GFP (green) and clathrin light chain-DsRed (red) that have been pre-treated for 1 h with 1 µM PAO or vehicle (DMSO) before treatment with 10 µM isoproterenol. e, Normalized mean fold increase over initial β-arrestin-2-GFP fluorescence in cells co-expressing Flag-β2AR when pre-treated for 1 h with 1 µM PAO following treatment with 10 µM isoproterenol (n = 12 cells from three independent experiments). f, Live-cell microscopy images of COS-1 cells co-expressing Flag-β2AR-V2R C tail (blue), β-arrestin-2-GFP (green), and clathrin light chain (CLC)-dsRed (red) that have been pre-treated for 1 h with 1 µM PAO before before treatment with 10 µM isoproterenol. g, Normalized average fold increase over initial β-arrestin-2-GFP fluorescence in cells coexpressing Flag-β2AR or Flag-β2AR-V2R when pre-treated for 1 h with 1 µM PAO following treatment with 10 µM isoproterenol (n = 12 cells from three independent experiments). a, d and f show representative images from three independent experiments. b, e and g show mean ± s.e.m. Scatter plots show overlay of mean and s.e.m.
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Extended Data Fig. 8 | sptPALM controls, MSD plots and cellular  model . a, Representative image of a clathrin mask (green) generated from a CLC-GFP image (red). b-e, Representative diffusion maps overlaid with the clathrin mask for HEK 293 cells treated with 10 µM isoproterenol and expressing PAmCherry-β1AR (b), PAmCherry-β2AR (c), β-arrestin-2-PAmCherry and Flag-β1AR (d), and β-arrestin-2-PAmCherry and Flag-β2AR (e). f, Distribution of diffusion coefficients (D) of false-positive detections from HEK 293 cells expressing Flag-β2AR and imaged under standard sptPALM acquisition conditions to determine contribution of false-positive detections in the experimental setup and analysis. g, Distribution of diffusion coefficients of PAmCherry-β2AR, PAmCherry-PLCδ1-PH and β-arrestin-2-PAmCherry in live cells imaged at 37 °C after treatment with 10 µM isoproterenol (n = 13, 21 and 8 cells, respectively). Black lines show diffusion coefficient profiles that have not been corrected for false-positive detections, showing limited contribution to the profiles. β-arrestin-2-PAmCherry and PAmCherry-PLCδ1-PH were co-expressed individually with Flag-β2AR. h, Average MSD plots derived from sptPALM analysis of PAmCherry-β1AR and PAmCherry-β2AR trajectories in HEK 293 cells treated with 10 µM isoproterenol (n = 8 and 13 cells, respectively). i, Distribution of diffusion coefficients of wild-type and CCS mutant β-arrestin-2-PAmCherry when co-expressed with Flag-β1AR in live HEK 293 cells imaged at 37 °C after treatment with 10 µM isoproterenol (n = 13 and 17 cells, respectively). Black lines show diffusion coefficient profiles that have not been corrected for falsepositive detections, showing limited contribution to the profiles. j, Average MSD plots derived from sptPALM analysis of wild-type and CCS mutant β-arrestin-2-PAmCherry trajectories in cells co-expressing Flag-β1AR and treated with 10 µM isoproterenol (n = 13 and 17 cells, respectively). k, Distribution of diffusion coefficients of wild-type and CCS mutant β-arrestin-2-PAmCherry when co-expressed with Flag-β2AR in live cells imaged at 37 °C after treatment with 10 µM isoproterenol (n = 21 and 10 cells, respectively). Black lines show diffusion coefficient profiles that have not been corrected for false-positive detections, showing limited contribution to the profiles. β-arrestin-2-PAmCherry diffusion coefficient profiles when activated by the β2AR are replotted from g. l, Average MSD plots derived from sptPALM analysis of wild-type and CCS mutant β-arrestin-2-PAmCherry trajectories in HEK 293 cells co-expressing Flag-β2AR and treated with 10 µM isoproterenol (n = 21 and 10 cells, respectively). m, n, Immobile (m) and mobile(n) β-arrestin-2-PAmCherry trajectory detections overlaid with a clathrin marker (red) in live cells co-expressing Flag-β1AR after treatment with 10 µM isoproterenol. o, p, Immobile (o) and mobile (p) β-arrestin-2-PAmCherry trajectory detections overlaid with a clathrin marker (red) in live cells co-expressing Flag-β2AR after treatment with 10 µM isoproterenol. Trajectory detections are false coloured based on the density of detections at each pixel. Error bars represent s.e.m; in some cases, error bars are smaller than the height of the symbol and are therefore not shown. Scale bars, 500 nm for sptPALM images. q, Proposed cellular pathway for catalytic activation of β-arrestin. r, Representative microscopy images of COS-1 cells coexpressing Flag-β2AR, β-arrestin-2-GFP (green) and clathrin light chainDsRed (red) that were treated with 10 µM isoproterenol for 3 min. Then, β-arrestin-2-GFP was photobleached in the indicated yellow region (inset; insets are also shown in Fig. 5h) . a-e, m-p and r show representative examples from at least three independent experiments. f-l show data as mean ± s.e.m.; in some cases, error bars are smaller than the height of the symbol and are, therefore, not shown. Scale bars; 500 nm for sptPALM images, 5 µm for larger FRAP images, 0.5 µm for inset FRAP images.
Extended Data Fig. 9 | Differences in the bioenergetics of catalytic versus scaffold mechanisms of regulated β-arrestin trafficking and β-arrestin-dependent activation of ERK1/2 promoted by catalytic activation. a, Schematic depicting the proposed co-existence of catalytic and scaffolding mechanisms of β-arrestin trafficking tuned according to tail binding affinity, emphasizing the difference in tail versus core interactions (shaded boxes). The tail interaction, which requires GPCR phosphorylation (Rp), drives scaffold formation by stabilizing GPCR-β-arrestin complex formation. The core interaction mediates catalysis by providing a kinetically favourable path for β-arrestin to remain at the plasma membrane irrespective of whether it is associated with a GPCR. The core interaction requires phosphoinositide binding to the β-arrestin C domain, which explains why the phosphoinositide requirement is specific to the catalytic mechanism and can be overcome by formation of a sufficiently stable scaffold complex requiring the phosphorylated GPCR tail. Primary energy inputs maintaining each proposed trafficking cycle are indicated by red arrows. The present results identify a specific requirement of the catalytic mechanism for phosphoinositide binding to the C domain but they do not exclude binding in the scaffold complex (which we think is likely). We also cannot presently rule out the possible existence of additional interaction(s) in the catalytic mechanism, such as phosphoinositide binding to the β-arrestin N domain, which has the potential to displace the β-arrestin C terminus 22 . b, Representative TIRF microscopy images of live cells (from three independent experiments) before and after treatment of cells expressing chimaeric Flag-tagged β1AR-V2Rs with 10 µM isoproterenol. Profiles of Flag-β2AR and β-arrestin-2-GFP average enrichment into CCSs in COS-1 cells expressing either an empty vector construct (c) or GRK2 (d) and treated with 10 µM isoproterenol (n = 15 or 12 cells, respectively, from three independent experiments). e, Difference in enrichment between β-arrestin-2-GFP and β2AR in cells shown in c and d, showing the effect of GRK2 overexpression. f, Representative western blot showing phosphorylated ERK1/2 and total ERK1/2 signal in extracts prepared from parental or β-arrestin-CRISPR-knockout HEK 293 cells expressing Flag-β1AR and exposed to 10 µM isoproterenol for the indicated time period. g, Quantification of ERK1/2 activation from the western blots in f (n = 5 independent experiments, P = 0.004 using a one-way ANOVA). h, Representative western blot showing phosphorylated ERK1/2 and total ERK1/2 signal in extracts prepared from parental or β-arrestin-CRISPR-knockout HEK 293 cells expressing Flag-β2AR and exposed to 10 µM isoproterenol for the indicated time period. i, Quantification of ERK1/2 activation from the western blots in h (n = 5 independent experiments). f and h show representative western blots from five independent experiments. Data are mean ± s.e.m. For gel source data, see Supplementary Fig. 1 . Error bars represent s.e.m. **P < 0.01.
1 nature research | reporting summary 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested Fiji 2.0 (https://fiji.sc/) was used to analyze microscopy data. Prism 7.0 was used for statistical analysis. spt-PALM analysis was performed using MetaMorph software (Molecular Devices) and a plug-in described in previous publications (https://www.nature.com/ncb/journal/ v14/n11/full/ncb2620.html and. Molecular dynamics simulations were visualized and analyzed using Visual Molecular Dynamics (VMD)
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability Associated raw data is indicated in the appropriate figure legends and a data availability statement is provided in the materials and methods section.
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Study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
In our experience, the sample sizes chosen are sufficient to obtain reliable results. These sample sizes are in line with the standard practice for data published in this field. Samples are always pooled across multiple independent biological replicates. Statistical analysis was applied after data collection. Exact sample size number for each experiment is reported in the figure legends.
Data exclusions After analysis of spt-PALM videos, cells that did not have at least 5 times more trajectories than the average false detection count were excluded from analysis as the contribution of photoactivated proteins was not sufficiently above the background of false detection. Similarly, spt-PALM videos where the density of single molecules was too high (cells with >20 000 trajectories) were excluded from further analysis to preserve the performances of the tracking software.
Replication
For each experiment, the findings were reliably reproduced and reported in the figure legends and materials and methods.
Randomization The study design did not require segregating sample groups in the beginning. The same cell culture preparation was used and sufficient aliquots of the same preparation (inherently random in distribution) were subjected to the relevant manipulations. Data collection and analysis was carried out on randomly selected samples.
Blinding
Investigators were blinded to sample identity during data collection and analysis for sptPALM experiments as reported in materials and methods. The investigator performing the microscopy and analyzing the data was blinded as to the identify of the samples.
Materials & experimental systems
Policy information about availability of materials n/a Involved in the study 
